| Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287) |
|---|
| 04/01/2009 | EP1349873B1 Modulation of il-2- and il-15-mediated t cell responses |
| 04/01/2009 | CN100473382C Oral dosage form for propiverine or pharmaceutically acceptable salts thereof with an extended release of the active ingredient |
| 03/31/2009 | US7511144 Reverse hydroxamic acid derivatives |
| 03/31/2009 | US7511121 Polymeric immunoglobulin fusion proteins that target low-affinity Fcγreceptors |
| 03/31/2009 | US7511074 A 5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid, acid ester, sulfonic acid or amide derivatives, for treating Alzheimer's disease, Parkinson's disease and Huntington's disease, epilepsy, stroke |
| 03/31/2009 | US7511073 Amines that inhibit a mammalian anandamide transporter, and methods of use thereof |
| 03/31/2009 | US7511047 Kinase inhibitors |
| 03/31/2009 | US7511012 Myostatin binding agents |
| 03/31/2009 | US7510825 Detecting perturbations and alterations of the normal organization of the cell plasma membrane (PNOM)-cells within a population of cells using a "perturbed membrane-binding compound" (PMBC) of given formula; e.g. monitoring aggressiveness of a tumor |
| 03/31/2009 | US7510711 Nucleotide sequence coding monoclonal antibody; anticancer agents; antiinflammatory agents; immunology disorders |
| 03/31/2009 | US7510702 Condensation aerosol for delivery of a drug selected from the group consisting of indomethacin, ketoprofen, celcoxib, rofecoxib, meclofenamic acid, fenoprofen, diflunisal, tolfenamic acid, naproxen, ibuprofen, flurbiprofen and nabumetone |
| 03/26/2009 | WO2009038110A1 Agent having neurotrophic factor-like activity |
| 03/26/2009 | WO2009036590A1 Compounds isolated from antrodia cinnamomea and use thereof |
| 03/26/2009 | US20090082384 Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
| 03/26/2009 | US20090082360 Use of tyrosine kinase inhibitors for treating CNS disorders |
| 03/26/2009 | US20090082270 myostatin antagonist protein is substantially serum stable for a period of at least 24 hours; treating individuals with muscle wasting conditions and provides further insight into the regulation of myostatin gene expression; muscular disorders |
| 03/26/2009 | US20090081730 Activatable recombinant neurotoxins |
| 03/26/2009 | US20090081123 Pharmaceutical compounds |
| 03/25/2009 | EP2039779A1 Screening method |
| 03/25/2009 | EP2039361A2 Use of immunomodulatory compounds |
| 03/25/2009 | EP1594523B1 Pharmaceutical compositions comprising botulinum toxin and human serum albumin |
| 03/25/2009 | EP1287035B1 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| 03/25/2009 | CN101392014A Bisamidocyanogen androstanes derivates, preparation method and use thereof |
| 03/24/2009 | US7507824 Spiro(2H-1benzopyran-2,4′-piperidine) derivates as glycine transport inhibitors |
| 03/24/2009 | US7507767 Sulfonamide-containing benzene derivatives which exhibit anti-inflammatory and immunodulatory activity |
| 03/24/2009 | US7507720 5-Beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia |
| 03/24/2009 | US7507414 Therapeutic polypeptide with prolonged shelf-life and increased half life for use in treatment of cell proliferative, cardiovascular, inflammatory and autoimmune disorders |
| 03/24/2009 | US7507398 Using condensation aerosol (MMAD of less than 5 microns) formed by vaporizing a thin layer of the drug on a solid support and condensing the vapor to treat anxiety, vertigo, alcohol or nicotine withdrawal, sedation, hot flashes, peptic ulcers or for hormone replacement therapy, or pregnancy prevention |
| 03/24/2009 | US7507397 Delivery of muscle relaxants through an inhalation route |
| 03/24/2009 | CA2377904C Medicament with a protective effect against oxidative-toxic substances, particularly against cardiotoxic substances |
| 03/19/2009 | WO2009036149A2 Methods for treatment of degenerative disease associated with apoptosis |
| 03/19/2009 | WO2009033250A1 Composition and method for increasing the anabolic state of muscle cells |
| 03/19/2009 | WO2008037258A8 [2-(6-flouro-1h-indol-3-ylsulfanyl)benzyl]methyl amine for the treatment of affective disorders |
| 03/19/2009 | US20090075981 INHIBITORS OF p38 |
| 03/19/2009 | US20090075938 Treatment of duchenne muscular dystrophy |
| 03/19/2009 | US20090075881 Fibrin gel for controlled release of pdgf and uses thereof |
| 03/19/2009 | US20090074859 Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| 03/19/2009 | US20090074842 Medicament patch |
| 03/19/2009 | US20090074841 Medicament-based patch |
| 03/18/2009 | EP2036895A1 Hsp90 inhibitor |
| 03/18/2009 | EP2036891A2 Isoquinoline inhibitors of P38 |
| 03/18/2009 | EP2036551A1 Agent for improving muscle power |
| 03/18/2009 | EP2034839A2 Treatment of neurodegenerative diseases through inhibiton of hsp90 |
| 03/18/2009 | EP1389096B1 Delivery of opioids through an inhalation route |
| 03/18/2009 | CN100469767C Bipiperidinyl-derivatives and their use as chemokine receptor inhibitors |
| 03/18/2009 | CN100469368C Use of adatanserin for treating neurogenerative disorders |
| 03/17/2009 | CA2502731C Sustained release composition for oral administration of drugs |
| 03/17/2009 | CA2360668C The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation |
| 03/12/2009 | WO2009033130A1 Mitochondrial compositions and uses thereof |
| 03/12/2009 | US20090069429 Compositions Comprising Alpha-Ketoglutarate and Their Use for Modulating Muscle Performance |
| 03/12/2009 | US20090069422 containing ethyl pyruvate and a therapeutically effective amount of at least one alpha -hydroxy branched-chain amino acid metabolite selected from alpha-hydroxyisocaproic acid, alpha -hydroxy- beta -methylvaleric acid, and alpha -hydroxy-isovaleric acid; time-release agents; nutritional supplement |
| 03/12/2009 | US20090069325 Piperidine Derivatives Useful as Modulators of Chemokine Receptor Activity |
| 03/12/2009 | US20090069301 Acridine and Quinoline Derivatives as Sirtuin Modulators |
| 03/12/2009 | US20090069238 Activatable clostridial toxins |
| 03/12/2009 | US20090069235 IGF-1 Fusion Polypeptides and Therapeutic Uses Thereof |
| 03/12/2009 | US20090068289 Formulation for menopausal women |
| 03/12/2009 | US20090068273 Prophylaxis of respiratory disorders such as asthma; composition with PDE4 inhibitor, corticosteroid hibitor or anticholinergic agent; 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol or salt |
| 03/12/2009 | US20090068205 Antiproliferative agents; anticancer agents; composition comprising antagonist of a human ErbB4 receptor, in admixture with a pharmaceutically acceptable carrier; antagonist selected from group consisting of an antibody produced by a hybridoma selected from the group containing HER4.10H1.1A1 |
| 03/12/2009 | US20090068193 Treatment And Prophylaxis With 4-1BB-Binding Agents |
| 03/12/2009 | US20090068162 Stationary Phase Antibody Arrays for Trace Protein Analysis |
| 03/12/2009 | US20090068156 Treatment of muscular dystrophy with cord blood cells |
| 03/12/2009 | US20090068152 Gene transfer for regulating smooth muscle tone |
| 03/12/2009 | US20090068139 LOOP PEPTIDE AND TGF alpha FOR STIMULATING STEM CELL PROLIFERATION AND MIGRATION |
| 03/12/2009 | CA2698755A1 Mitochondrial compositions and uses thereof |
| 03/11/2009 | EP2034009A2 Compositions and methods for restoring immune responsiveness in patients with immunological defects basing on cd3/cd28 costimulation |
| 03/11/2009 | EP2033951A2 2-Piperazine-pyridines useful for treating pain |
| 03/11/2009 | EP2033644A1 Spiroindene and spiroindane compounds |
| 03/11/2009 | EP2033634A1 Agent for increasing testosterone level |
| 03/11/2009 | EP2032157A1 High frequency application of neurotoxic component of botulinum toxin |
| 03/11/2009 | EP1631574B1 Colchicoside analogues |
| 03/11/2009 | EP1485364B1 Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase |
| 03/11/2009 | CN101380464A Method for treating a movement disorder |
| 03/11/2009 | CN100467447C Thioamide compound or its salt and cytokine production inhibitor containing the same |
| 03/11/2009 | CN100467058C Pharmaceutical and cosmetic compositions comprising PLGF-1 |
| 03/11/2009 | CA2639412A1 Prostaglandin e2 modulation and uses thereof |
| 03/10/2009 | US7501417 Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase |
| 03/10/2009 | US7501399 Immunoeffector compounds |
| 03/10/2009 | US7501115 Providing a tissue removal system; removing adipose tissue from a patient using the tissue removal system, the adipose tissue having a concentration of stem cells; processing at least a part of the adipose tissue to obtain a concentration |
| 03/10/2009 | CA2345069C 2-phenylpyran-4-one derivatives |
| 03/10/2009 | CA2289851C Compounds and methods for the inhibition of the expression of vcam-1 |
| 03/05/2009 | WO2008156685A3 Tendon stem cells |
| 03/05/2009 | WO2008108322A3 Composition and method for protecting mitochondria |
| 03/05/2009 | WO2008030505A8 Methods and compositions for the treatment of antibody mediated neuropathies |
| 03/05/2009 | US20090062354 Method of increasing the extent of absorption of tizanidine |
| 03/05/2009 | US20090060971 Methods of treating a trauma or disorder of the knee joint by local administration and sustained-delivery of a biological agent |
| 03/05/2009 | US20090060953 Methods for using tetanus toxin for beneficial purposes in animals (mammals) |
| 03/04/2009 | EP1931223B1 Nutrition comprising betaine against muscle wasting |
| 03/04/2009 | EP1740198A4 Anti-aging effects of substance p |
| 03/04/2009 | EP1519957B1 Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair |
| 03/04/2009 | EP1490071B1 Therapeutic uses of sapogenins |
| 03/04/2009 | EP1485370B1 Amino-derivatives as novel inhibitors of histone deacetylase |
| 03/04/2009 | CN101379086A Antagonist antibodies against GDF-8 and uses in treatment of ALS and other GDF-8-associated disorders |
| 03/04/2009 | CN101378739A Use of nitrooxyderivative of drug for the treatment of muscular dystrophies |
| 03/04/2009 | CN100464782C A therapeutic agent for fibromyalgia |
| 03/04/2009 | CN100464756C An application of fucoidan in the preparation of medicines and health-care products for preventing and treating neurodegenerative diseases |
| 03/03/2009 | US7498406 4-(N (S-glutathionylacetyl)amino)phenylarsenoxide (GSAO) and derivatives; antiinflammatory and antitumor agents; blood and autoimmune disorders; viral infections; anticoagulants |
| 03/03/2009 | US7498334 Pyrrolopyrimidines as phosphodiesterase VII inhibitors |
| 03/03/2009 | US7498301 Administering or applying anserine for treating muscle spasm, localized swelling, inflammation, joint pains, muscle fatigue, stress and myocardial infarction optionally with a diuretic |
| 03/03/2009 | US7498032 Methods for treating immune disorders or cancer with anti-CD40 antibodies |
| 03/03/2009 | CA2543986C Norepinephrine reuptake inhibitors and methods of using the same |